Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics

Suberoylanilide hydroxamic acid (SAHA), a pan HDAC inhibitor, has been approved by the Food and Drug Administration (FDA) to treat cutaneous T cell lymphoma (CTCL). Nevertheless, the mechanisms underlying the therapeutic effects of SAHA on tumors are yet not fully understood. Protein phosphorylation...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huichao, Fu, Ying, Zhang, Ye, Peng, Fang, Lu, Miaolong, Feng, Yilu, Chen, Lin, Chen, Zhuchu, Li, Maoyu, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726116/
https://www.ncbi.nlm.nih.gov/pubmed/33324635
http://dx.doi.org/10.3389/fcell.2020.577784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726116/
https://www.ncbi.nlm.nih.gov/pubmed/33324635
http://dx.doi.org/10.3389/fcell.2020.577784

Ejemplares similares